Patents by Inventor Jerry McKee Adams

Jerry McKee Adams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BENZOTHIAZOLE COMPOUNDS
    Publication number: 20100197711
    Abstract: The present invention relates to benzothiazole compounds that mimic the activity of BH3 only proteins and are capable of binding to and neutralizing pro survival Bcl 2 proteins. The invention also relates to the use of such compounds in the regulation of cell death or cell survival and the treatment and/or prophylaxis of diseases or conditions associated with the deregulation of cell death or cell survival.
    Type: Application
    Filed: September 27, 2007
    Publication date: August 5, 2010
    Inventors: Keith Geoffrey Watson, Guillaume Laurent Lessene, Jonathan Bayldon Baell, David Ching Siang Huang, Ian Philip Street, Jerry McKee Adams, Peter Malcolm Colman, Brad Edmund Sleebs, Brian John Smith, Peter Edward Czabotar
  • Mammalian gene, bcl-w, belongs to the bcl-2 family of apoptosis-controlling genes
    Patent number: 7166698
    Abstract: The present invention is broadly directed to therapeutic molecules capable of inter alia modulating apoptosis in mammalian cells. The therapeutic molecules of the present invention encompass genetic sequences and chemical entities capable of regulating expression of a novel mammalian gene belonging to the bcl-2 family and which promotes cell survival. The therapeutic molecules of the present invention may have further utility in delaying cell cycle entry. In addition, the present invention extends to chemical entities capable of modulating activity and function of the translation product of said novel gene of the bcl-2 family. The present invention also extends to the translation product of the novel gene of the bcl-2 family and its use in, for example, therapy, diagnosis, antibody generation and as a screening tool for therapeutic molecules capable of modulating physiological cell death or survival and/or modulating cell cycle entry.
    Type: Grant
    Filed: August 9, 2001
    Date of Patent: January 23, 2007
    Assignee: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Suzanne Cory, Jerry McKee Adams, Leonie M. Gibson, Shaun P. Holmgreen
  • Mammalian gene, BCL-W, belongs to the BCL-2 family of apoptosis-controlling genes
    Patent number: 6790637
    Abstract: The present invention is broadly directed to therapeutic molecules capable of inter alia modulating apoptosis in mammalian cells. The therapeutic molecules of the present invention encompass genetic sequences and chemical entities capable of regulating expression of a novel mammalian gene belonging to the bcl-2 family and which promotes cell survival. The therapeutic molecules of the present invention may have further utility in delaying cell cycle entry. In addition, the present invention extends to chemical entities capable of modulating activity and function of the translation product of said novel gene of the bcl-2 family. The present invention also extends to the translation product of the novel gene of the bcl-2 family and its use in, for example, therapy, diagnosis, antibody generation and as a screening tool for therapeutic molecules capable of modulating physiological cell death or survival and/or modulating cell cycle entry.
    Type: Grant
    Filed: March 29, 1999
    Date of Patent: September 14, 2004
    Assignee: Cerylid Pty., Ltd.
    Inventors: Suzanne Cory, Jerry McKee Adams, Leonie M. Gibson, Shaun P. Holmgreen
  • Novel mammalian gene,bcl-w, belongs to the bcl-2 family of apoptosis-controlling genes
    Publication number: 20020119943
    Abstract: The present invention is broadly directed to therapeutic molecules capable of inter alia modulating apoptosis in mammalian cells. The therapeutic molecules of the present invention encompass genetic sequences and chemical entities capable of regulating expression of a novel mammalian gene belonging to the bcl-2 family and which promotes cell survival. The therapeutic molecules of the present invention may have further utility in delaying cell cycle entry. In addition, the present invention extends to chemical entities capable of modulating activity and function of the translation product of said novel gene of the bcl-2 family. The present invention also extends to the translation product of the novel gene of the bcl-2 family and its use in, for example, therapy, diagnosis, antibody generation and as a screening tool for therapeutic molecules capable of modulating physiological cell death or survival and/or modulating cell cycle entry.
    Type: Application
    Filed: August 9, 2001
    Publication date: August 29, 2002
    Inventors: Suzanne Cory, Jerry McKee Adams, Leonie M. Gibson, Shaun P. Holmgreen